Literature DB >> 36002495

Psychedelic drugs take on depression.

Cassandra Willyard.   

Abstract

Entities:  

Keywords:  Depression; Drug discovery; Psychiatric disorders; Psychology

Mesh：

Substances：

Year:  2022        PMID： 36002495     DOI： 10.1038/d41586-022-02205-w

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  8 in total

1.  Trial of Psilocybin versus Escitalopram for Depression.

Authors:  Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt
Journal:  N Engl J Med       Date:  2021-04-15       Impact factor: 91.245

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

3.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

Authors:  Vanina Popova; Ella J Daly; Madhukar Trivedi; Kimberly Cooper; Rosanne Lane; Pilar Lim; Christine Mazzucco; David Hough; Michael E Thase; Richard C Shelton; Patricio Molero; Eduard Vieta; Malek Bajbouj; Husseini Manji; Wayne C Drevets; Jaskaran B Singh
Journal:  Am J Psychiatry       Date:  2019-05-21       Impact factor: 18.112

4.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Madhukar H Trivedi; Adam Janik; Honglan Li; Yun Zhang; Xiang Li; Rosanne Lane; Pilar Lim; Anna R Duca; David Hough; Michael E Thase; John Zajecka; Andrew Winokur; Ilona Divacka; Andrea Fagiolini; Wieslaw J Cubala; István Bitter; Pierre Blier; Richard C Shelton; Patricio Molero; Husseini Manji; Wayne C Drevets; Jaskaran B Singh
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

5.  A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.

Authors:  L Alison McInnes; Jimmy J Qian; Rishab S Gargeya; Charles DeBattista; Boris D Heifets
Journal:  J Affect Disord       Date:  2022-01-11       Impact factor: 6.533

6.  Increased global integration in the brain after psilocybin therapy for depression.

Authors:  Richard E Daws; Christopher Timmermann; Bruna Giribaldi; James D Sexton; Matthew B Wall; David Erritzoe; Leor Roseman; David Nutt; Robin Carhart-Harris
Journal:  Nat Med       Date:  2022-04-11       Impact factor: 87.241

7.  Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups? A protocol for a meta-epidemiological study of PDE-5 inhibitors.

Authors:  Frederik Feys; Geertruida E Bekkering; Kavita Singh; Dirk Devroey
Journal:  Syst Rev       Date:  2012-11-14

8.  Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines.

Authors:  Jaclyn N Highland; Patrick J Morris; Kylie M Konrath; Lace M Riggs; Natalie R Hagen; Panos Zanos; Chris F Powels; Ruin Moaddel; Craig J Thomas; Amy Q Wang; Todd D Gould
Journal:  ACS Chem Neurosci       Date:  2022-02-03       Impact factor: 4.418
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.